PTSD Clinical Trial
Official title:
Geodon (Ziprasidone) for Posttraumatic Stress Disorder
Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiveness of Geodon in civilian men and women who suffer from severe PTSD. Response to ziprasidone or placebo will be measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8).
PTSD is a common disorder with 10% lifetime prevalence among Americans. The major causes of
PTSD are sexual assault, accidents, disasters Despite this public health burden, only two
drugs, sertraline (Zoloft) and paroxetine (Paxil), are approved by the FDA for the treatment
of PTSD. New options for the treatment of PTSD are much needed. Approximately half of
patients with PTSD respond to Zoloft and Paxil. Many patients experience psychotic symptoms
with PTSD, which may not respond to treatment to Zoloft and Paxil.
Though classified as an anxiety disorder in the DSM-IV, PTSD is accompanied by psychotic
symptoms in almost half of patients (Butler et al 1996; Hamner et al 1999, Lindley et al
2000). Also, PTSD has an extensive comorbidity with major depressive disorder (Davis et al
2000). While Geodon is approved by the FDA in the United States for the treatment of
psychosis, it has not been evaluated for the treatment of PTSD . A clinical trial of Geodon
in PTSD will help delineate the potential antidepressant spectrum of efficacy of Geodon as
well as its anxiolytic profile.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03962504 -
Written Exposure Therapy Versus Prolonged Exposure: a Non-inferiority Trial
|
N/A | |
| Completed |
NCT01995123 -
Behavioral Activation for Smoking Cessation in PTSD
|
N/A | |
| Not yet recruiting |
NCT06278922 -
Evaluating Signs of Safety: A Deaf-Accessible Therapy Toolkit for AUD and Trauma
|
N/A | |
| Completed |
NCT04597450 -
Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)
|
Phase 1 | |
| Completed |
NCT03593772 -
Mission Reconnect- Delivering a Mobile and Web Based Self Directed Complementary And Integrative Health Program to Veterans and Their Partners to Manage Pain and PTSD
|
N/A | |
| Completed |
NCT03429166 -
Connecting Women to Care: Home-based Psychotherapy for Women With MST Living in Rural Areas
|
N/A | |
| Recruiting |
NCT04317820 -
Deep Brain Reorienting in Post-traumatic Stress Disorder
|
N/A | |
| Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
| Completed |
NCT03504722 -
Evaluating the Feasibility of RESCUE: An Adjunctive HAI-Based Intervention for Veterans With PTSD
|
N/A | |
| Completed |
NCT04305353 -
Intensive Care Unit (ICU) Diary Project
|
N/A | |
| Completed |
NCT03113890 -
McLean and Genomind Prospective Study
|
N/A | |
| Withdrawn |
NCT05173831 -
Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans
|
Phase 2 | |
| Not yet recruiting |
NCT04056767 -
Changes in Digital Phenotype During PE Therapy
|
||
| Withdrawn |
NCT03924297 -
Chilipad for Sleep and Symptoms of PTSD
|
N/A | |
| Withdrawn |
NCT03216356 -
Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD
|
Phase 2/Phase 3 | |
| Completed |
NCT03343028 -
Biomarker Establishment for Superior Treatment of PTSD
|
||
| Completed |
NCT03158558 -
Intensive Weekend Retreat Multi-Couple Group Therapy for PTSD
|
N/A | |
| Completed |
NCT02370173 -
A Non-Pharmacological Method for Enhancing Sleep in PTSD
|
N/A | |
| Withdrawn |
NCT01957371 -
Mindful Yoga Therapy for Veterans With PTSD and Pain
|
N/A | |
| Completed |
NCT01911585 -
Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure
|
N/A |